Histone Deacetylase Inhibitor Induced Radiation Sensitization Effects on Human Cancer Cells after Photon and Hadron Radiation Exposure

Int J Mol Sci. 2018 Feb 7;19(2):496. doi: 10.3390/ijms19020496.

Abstract

Suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase inhibitor, which has been widely utilized throughout the cancer research field. SAHA-induced radiosensitization in normal human fibroblasts AG1522 and lung carcinoma cells A549 were evaluated with a combination of γ-rays, proton, and carbon ion exposure. Growth delay was observed in both cell lines during SAHA treatment; 2 μM SAHA treatment decreased clonogenicity and induced cell cycle block in G1 phase but 0.2 μM SAHA treatment did not show either of them. Low LET (Linear Energy Transfer) irradiated A549 cells showed radiosensitization effects on cell killing in cycling and G1 phase with 0.2 or 2 μM SAHA pretreatment. In contrast, minimal sensitization was observed in normal human cells after low and high LET radiation exposure. The potentially lethal damage repair was not affected by SAHA treatment. SAHA treatment reduced the rate of γ-H2AX foci disappearance and suppressed RAD51 and RPA (Replication Protein A) focus formation. Suppression of DNA double strand break repair by SAHA did not result in the differences of SAHA-induced radiosensitization between human cancer cells and normal cells. In conclusion, our results suggest SAHA treatment will sensitize cancer cells to low and high LET radiation with minimum effects to normal cells.

Keywords: SAHA; carbon ions; proton.

MeSH terms

  • A549 Cells
  • Biomarkers, Tumor / analysis
  • Cell Cycle / drug effects
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • DNA Breaks, Double-Stranded / drug effects
  • DNA Repair / drug effects
  • Elementary Particles / therapeutic use
  • Fibroblasts / drug effects
  • Gamma Rays / therapeutic use
  • Histone Deacetylase Inhibitors / adverse effects
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Hydroxamic Acids / adverse effects
  • Hydroxamic Acids / pharmacology*
  • Neoplasms / radiotherapy*
  • Photons / therapeutic use
  • Radiation-Sensitizing Agents / adverse effects
  • Radiation-Sensitizing Agents / pharmacology*
  • Vorinostat

Substances

  • Biomarkers, Tumor
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Radiation-Sensitizing Agents
  • Vorinostat